2. Academic Validation
  3. Huang-Lian-Jie-Du decoction enhances Capecitabine-Oxaliplatin efficacy via Akkermansia muciniphila and CD8+ T cells in colorectal cancer

Huang-Lian-Jie-Du decoction enhances Capecitabine-Oxaliplatin efficacy via Akkermansia muciniphila and CD8+ T cells in colorectal cancer

  • Phytomedicine. 2025 Sep 4:148:157233. doi: 10.1016/j.phymed.2025.157233.
Yan Chen 1,  Xinjie Lai 2,  Yijie Zhang 2,  Cheng Qiu 3,  Ying Qin 4,  Tingting Fan 5,  Tongmeng Yan 6,  Mengmeng Dai 3,  Qinsheng Sun 2,  Zhihong Jiang 7,  Yuyang Jiang 8
Affiliations

Affiliations

  • 1 Guangdong Key Laboratory of Chinese Medicine Ingredients and Gut Microbiomics, School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China; State Key Laboratory of Chemical Oncogenomics, Tsinghua Shenzhen International Graduate School, Shenzhen, China.
  • 2 Guangdong Key Laboratory of Chinese Medicine Ingredients and Gut Microbiomics, School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
  • 3 State Key Laboratory of Chemical Oncogenomics, Tsinghua Shenzhen International Graduate School, Shenzhen, China.
  • 4 Department of Gastrointestinal Surgery, Shenzhen Second People's Hospital, Shenzhen, China.
  • 5 Institute of Biomedical Health Technology and Engineering, Shenzhen Bay Laboratory, Shenzhen, China.
  • 6 State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau SAR, China.
  • 7 State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau SAR, China; National Innovation Center for Molecular Drug, Shenzhen, China. Electronic address: zhjiang@must.edu.mo.
  • 8 Guangdong Key Laboratory of Chinese Medicine Ingredients and Gut Microbiomics, School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China; State Key Laboratory of Chemical Oncogenomics, Tsinghua Shenzhen International Graduate School, Shenzhen, China. Electronic address: jiangyy@sz.tsinghua.edu.cn.
PMID: 40972261 DOI: 10.1016/j.phymed.2025.157233
Abstract

Background: The Capecitabine plus Oxaliplatin (XELOX) regimen is a first-line chemotherapy for colorectal Cancer (CRC), but drug resistance remains a major therapeutic challenge. Our clinical observations suggest a positive correlation between fecal Akkermansia muciniphila bundance and chemotherapy responsiveness. Huang-Lian-Jie-Du Decoction (HLJDD), a traditional Chinese medicine with gut microbiota-modulating properties, may serve as a chemosensitizer, though its mechanisms are unclear.

Purpose: This study aimed to evaluate whether HLJDD enhances XELOX efficacy in CRC and to elucidate the role of gut microbiota, particularly A. muciniphila, in this synergistic effect.

Methods: CRC patients receiving XELOX were analyzed for fecal A. muciniphila levels and treatment response. In MC38 and CT26 tumor-bearing mice, HLJDD was administered alone or combined with XELOX. Gut microbiota composition (16S rRNA Sequencing), serum metabolites (untargeted metabolomics), and tumor immune infiltration (immunohistochemistry) were assessed. Co-housing experiments and direct A. muciniphila supplementation were conducted to validate microbiota-mediated mechanisms.

Results: Higher baseline A. muciniphila abundance correlated with improved XELOX response in CRC patients. HLJDD selectively promoted A. muciniphila proliferation in vitro and in vivo. In murine models, HLJDD synergized with XELOX, significantly suppressing tumor growth vs. XELOX alone. Multi-omics analyses revealed HLJDD-driven enrichment of tryptophan metabolism and increased 5-hydroxytryptophan levels, accompanied by enhanced CD8+ T cell infiltration and interferon-γ upregulation in tumors. Cohousing with HLJDD-treated mice or direct A. muciniphila gavage recapitulated the chemosensitizing effects, confirming gut microbiota's pivotal role.

Conclusion: This study unveils a novel and multi-faceted therapeutic strategy: HLJDD overcomes XELOX resistance by specifically remodeling gut microbiota to expand A. muciniphila, which subsequently activates tryptophan metabolism and anti-tumor immunity. Our findings provide robust preclinical evidence for combining HLJDD with XELOX as a promising innovative approach to overcome CRC chemoresistance, with A. muciniphila serving as a predictive biomarker and potential therapeutic target.

Keywords

Akkermansia muciniphila; CD8(+) T cells; Colorectal cancer; Huang-Lian-Jie-Du Decoction; IFN-γ; XELOX chemotherapy.

Figures
Products